content: <HTML>
  <HEAD>
  <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font-size: 10pt">
  
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">SECURITIES AND EXCHANGE
  COMMISSION</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">Washington, D.C. 20549</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">FORM 8-K</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">CURRENT REPORT</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">Pursuant to Section 13 or 15(d)</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">of the Securities Exchange Act of 1934</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">Date of Report (date of earliest event
  reported):</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">November 25, 2015</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: white">
      <TD COLSPAN="5" STYLE="margin: 0; text-align: center; text-indent: 0; border-bottom: Black 1pt solid"><B>EVENT
      CARDIO GROUP INC.</B></TD></TR>
  <TR STYLE="background-color: white">
      <TD COLSPAN="5" STYLE="margin: 0; text-align: center; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0">(Exact name of registrant as specified in its charter)</P>
                                                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="margin: 0; text-align: center; text-indent: 0; width: 30%; border-bottom: Black 1pt solid"><B>Nevada</B></TD>
      <TD STYLE="width: 5%; padding-bottom: 1pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="margin: 0; text-align: center; text-indent: 0; width: 30%; border-bottom: Black 1pt solid"><B>0-52518</B></TD>
      <TD STYLE="width: 5%; padding-bottom: 1pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="margin: 0; text-align: center; text-indent: 0; width: 30%; border-bottom: Black 1pt solid"><B>20-8051714</B></TD></TR>
  <TR>
      <TD STYLE="margin: 0; text-align: center; text-indent: 0">(State or other jurisdiction of Incorporation)</TD>
      <TD STYLE="vertical-align: top; padding-bottom: 10pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="margin: 0; text-align: center; text-indent: 0">(Commission File Number)</TD>
      <TD STYLE="vertical-align: top; padding-bottom: 10pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="margin: 0; text-align: center; text-indent: 0">(I.R.S. Employer Identification No.)</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="margin: 0; text-align: center; text-indent: 0; width: 45%; border-bottom: Black 1pt solid"><B>20D Southport Lane, Boynton Beach, Florida 33436</B></TD>
      <TD STYLE="width: 10%; padding-bottom: 1pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="margin: 0; text-align: center; text-indent: 0; width: 45%; border-bottom: Black 1pt solid"><B>33436</B></TD></TR>
  </TABLE>
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0"><B>2798 Thamesgate Dr.</B> <B>Mississauga,
  Ontario, Canada L4T 4E8</B> &nbsp;&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">(Former address of principal executive offices)</P>
  
  <P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">Check the appropriate box below if the Form 8-K filing is
  intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
  Instruction A.2. below):</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">[ ]&nbsp;Written communications pursuant to Rule 425
  under the Securities Act (17 CFR 230.425)</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">[ ]&nbsp;Soliciting material pursuant to Rule 14a-12 under the
  Exchange Act (17&nbsp;&nbsp;&nbsp;CFR 240.14a-12)</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">[ ]&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">[ ]&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))&nbsp;</P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>FORWARD LOOKING STATEMENTS</B></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="background-color: white"><B><I>Information
  included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section
  21E of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). This information may involve known and
  unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Event Cardio
  Group Inc. and its subsidiaries (collectively, &#8220;ECGI&#8221;, &#8220;We&#8221;, &#8220;Our&#8221; or the &#8220;Company&#8221;)
  to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements.
  Forward-looking statements, which involve assumptions and describe ECGI&#8217;s future plans, strategies and expectations, are
  generally identifiable by use of words &quot;may,&quot; &quot;should,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;estimate,&quot;
  &quot;believe,&quot; &quot;intend&quot; or &quot;project&quot; or the negative of these words or other variations on these words
  or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance
  that any projections or other expectations included in any forward-looking statements will come to pass. ECGI&#8217;s actual results
  could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except
  as required by applicable laws, ECGI undertakes no obligation to update publicly any forward-looking statements for any reason,
  even if new information becomes available or other events occur in the future.</I></B></FONT></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><B>&nbsp;</B></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><B>Item 8.01 Other Events.</B></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><I>Completion of NowCardio Field Audit</I></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">On November 26 and 27, 2015, Contex International Technologies
  (Canada) Inc., the engineering firm engaged by Event Cardio Group, Inc., to develop its NowCardio&reg; heart monitor, completed&nbsp;
  a Stage 2 Audit, last of a series of audits, conducted by the registrar BSI Group Canada Inc.&nbsp; No non-conformances were noted
  in the audit, and the Company anticipates that Contex will receive ISO 9001 and ISO 13485/CMDCAS Certificates in the coming weeks.
  These certificates are required to apply to Health Canada for certification of the NowCardio&reg; System&nbsp;as a Class II Medical
  Device, and furthermore, to license manufacturing and distribution within Canada.&nbsp;In addition to obtaining the ISO/CMDCAS Certificates, Contex must also submit the NowCardio&reg; device to an outside
  lab for regulatory testing. NowCardio&reg; has already passed interim testing of development prototypes at the lab.</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">The Company expects that Contex will receive the ISO/CMDCAS Certificates
  by the end of the year at which time it will make the submission to Health Canada. Although there can be no assurances, the Company
  currently anticipates that it will receive the necessary approvals and be authorized to sell NowCardio&reg; in Canada in early
  February 2016.</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><I>Dispute with Medpac</I></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">On November 25, 2015, the Company received a notice from Medpac
  Asia Pacific Pty Ltd. alleging that the Company was in default of representations and covenants contained in the Subscription
  Agreement dated April 27, 2015, whereby Medpac purchased the Company&#8217;s $500,000 Convertible Note. Specifically, the notice
  alleges that the Company did not have the authority to grant sublicenses with respect to certain territories as to which Medpac
  was to acquire rights and that the Company has failed to pay to the engineers engaged to develop NowCardio&reg; and a production
  line for Breastcare&reg; the amounts required by the Subscription Agreement. The notice requested payment of the monies due on
  December 30, 2015.</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">The Company believes that it had the necessary
  authority to grant the rights intended to be granted to Medpac and that it has made the required payments to its engineering firms.
  Consequently, there is no basis for the allegation that it is in default of its obligations to Medpac. The Company is currently
  in discussion with Medpac to resolve these issues but, if they are not satisfactorily resolved, intends to contest them vigorously.</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><I></I></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><I>Dispute with Life Medical </I></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">On November 30, 2015, the Company received a notice from Life Medical
  Technologies, Inc., alleging that it is in default of its obligations under the License Agreement between the Company and Life
  Medical. Specifically, Life Medical alleges that the $500,000 received from Medpac in consideration of the Convertible Promissory
  Note issued to Medpac in April 2015 constitutes an advance royalty and that a portion of the funds were to be paid to Life Medical.
  In addition, Life Medical alleges that the Company or its licensee has failed to expend the requisite amounts necessary to maintain
  exclusivity in certain of the countries which are the subject of the agreements between the Company and Medpac and therefore,
  the Company is no longer entitled to retain these territories and is obligated to pay Life Medical amounts provided for in the
  License between Life Medical and the Company.</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="color: windowtext">The Company believes Life Medical&#8217;s
  claim regarding the monies received from Medpac has no merit and that, among other things, it is entitled to offset against any
  amounts that may be due Life Medical amounts that it has paid to creditors of Life Medical. Further, the Company believes that
  it and Medpac have paid the amounts necessary to maintain the rights to distribute BreastCare</FONT>&reg; in Australia and that,
  among other reasons, the failure of the parties to <FONT STYLE="color: windowtext">due to develop a manufacturing line to produce
  the BreastCare</FONT>&reg; device has extended the Company&#8217;s and Medpac&#8217;s obligations to expend funds in furtherance
  of the marketing of the device in Australia. <FONT STYLE="color: windowtext">If Life Medical pursues its claims, the Company will
  defend them vigorously and pursue any counterclaims it may have against Life Medical for actions which it believes were intentionally
  intended to interfere with the Company&#8217;s attempts to raise the financing necessary to advance its products.</FONT></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0"><I>Julie Singleton</I></P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">The Company had previously announced that Julie Singleton, an investor
  in MedPac, had agreed to serve as the CEO of its BreatCare Division and as a member of its Board of Directors. In light of the
  current dispute between the Company and Medpac, Ms. Singleton will not be serving in either of such positions.</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">SIGNATURES</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>
  
  <P STYLE="margin: 0; text-align: justify; text-indent: 20pt">Pursuant
  to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunto duly authorized.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Dated: December 4, 2015</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="line-height: 115%">EVENT CARDIO GROUP INC.</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 52%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 2%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 35%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 11%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">By:</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%">/s/&nbsp;John Bentivoglio</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">John Bentivoglio</TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">Chief Executive Officer</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 4; Options: Last -->
      <DIV STYLE="margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "ecgi8k120415.htm", "secsgml_size_bytes": 17147}]
metadata_filer: {"company-data": {"conformed-name": "Event Cardio Group Inc.", "cik": "0001394130", "assigned-sic": "1000", "irs-number": "208051714", "state-of-incorporation": "NV", "fiscal-year-end": "0831"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52518", "film-number": "151270771"}, "business-address": {"street1": "2798 THAMESGATE DR.", "city": "MISSISSAUGA", "state": "A6", "zip": "L4T 4E8", "phone": "289-407-4377"}, "mail-address": {"street1": "2798 THAMESGATE DR.", "city": "MISSISSAUGA", "state": "A6", "zip": "L4T 4E8"}, "former-company": [{"former-conformed-name": "Sunrise Holdings LTD", "date-changed": "20080404"}, {"former-conformed-name": "Sunrise Mining CORP", "date-changed": "20070322"}]}
text: SECURITIES AND EXCHANGE
  COMMISSION
  Washington, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15(d)
  of the Securities Exchange Act of 1934
  Date of Report (date of earliest event
  reported):
  November 25, 2015
  EVENT
      CARDIO GROUP INC.
  (Exact name of registrant as specified in its charter)
  Nevada
  0-52518
  20-8051714
  (State or other jurisdiction of Incorporation)
  (Commission File Number)
  (I.R.S. Employer Identification No.)
  20D Southport Lane, Boynton Beach, Florida 33436
  33436
  2798 Thamesgate Dr.
  Mississauga,
  Ontario, Canada L4T 4E8
  (Former address of principal executive offices)
  Check the appropriate box below if the Form 8-K filing is
  intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
  Instruction A.2. below):
  [ ] Written communications pursuant to Rule 425
  under the Securities Act (17 CFR 230.425)
  [ ] Soliciting material pursuant to Rule 14a-12 under the
  Exchange Act (17   CFR 240.14a-12)
  [ ] Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))
  [ ] Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))
  FORWARD LOOKING STATEMENTS
  Information
  included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section
  21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and
  unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Event Cardio
  Group Inc. and its subsidiaries (collectively, "ECGI", "We", "Our" or the "Company")
  to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements.
  Forward-looking statements, which involve assumptions and describe ECGI's future plans, strategies and expectations, are
  generally identifiable by use of words "may," "should," "expect," "anticipate," "estimate,"
  "believe," "intend" or "project" or the negative of these words or other variations on these words
  or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance
  that any projections or other expectations included in any forward-looking statements will come to pass. ECGI's actual results
  could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except
  as required by applicable laws, ECGI undertakes no obligation to update publicly any forward-looking statements for any reason,
  even if new information becomes available or other events occur in the future.
  Item 8.01 Other Events.
  Completion of NowCardio Field Audit
  On November 26 and 27, 2015, Contex International Technologies
  (Canada) Inc., the engineering firm engaged by Event Cardio Group, Inc., to develop its NowCardio® heart monitor, completed 
  a Stage 2 Audit, last of a series of audits, conducted by the registrar BSI Group Canada Inc.  No non-conformances were noted
  in the audit, and the Company anticipates that Contex will receive ISO 9001 and ISO 13485/CMDCAS Certificates in the coming weeks.
  These certificates are required to apply to Health Canada for certification of the NowCardio® System as a Class II Medical
  Device, and furthermore, to license manufacturing and distribution within Canada. In addition to obtaining the ISO/CMDCAS Certificates, Contex must also submit the NowCardio® device to an outside
  lab for regulatory testing. NowCardio® has already passed interim testing of development prototypes at the lab.
  The Company expects that Contex will receive the ISO/CMDCAS Certificates
  by the end of the year at which time it will make the submission to Health Canada. Although there can be no assurances, the Company
  currently anticipates that it will receive the necessary approvals and be authorized to sell NowCardio® in Canada in early
  February 2016.
  Dispute with Medpac
  On November 25, 2015, the Company received a notice from Medpac
  Asia Pacific Pty Ltd. alleging that the Company was in default of representations and covenants contained in the Subscription
  Agreement dated April 27, 2015, whereby Medpac purchased the Company's $500,000 Convertible Note. Specifically, the notice
  alleges that the Company did not have the authority to grant sublicenses with respect to certain territories as to which Medpac
  was to acquire rights and that the Company has failed to pay to the engineers engaged to develop NowCardio® and a production
  line for Breastcare® the amounts required by the Subscription Agreement. The notice requested payment of the monies due on
  December 30, 2015.
  The Company believes that it had the necessary
  authority to grant the rights intended to be granted to Medpac and that it has made the required payments to its engineering firms.
  Consequently, there is no basis for the allegation that it is in default of its obligations to Medpac. The Company is currently
  in discussion with Medpac to resolve these issues but, if they are not satisfactorily resolved, intends to contest them vigorously.
  Dispute with Life Medical
  On November 30, 2015, the Company received a notice from Life Medical
  Technologies, Inc., alleging that it is in default of its obligations under the License Agreement between the Company and Life
  Medical. Specifically, Life Medical alleges that the $500,000 received from Medpac in consideration of the Convertible Promissory
  Note issued to Medpac in April 2015 constitutes an advance royalty and that a portion of the funds were to be paid to Life Medical.
  In addition, Life Medical alleges that the Company or its licensee has failed to expend the requisite amounts necessary to maintain
  exclusivity in certain of the countries which are the subject of the agreements between the Company and Medpac and therefore,
  the Company is no longer entitled to retain these territories and is obligated to pay Life Medical amounts provided for in the
  License between Life Medical and the Company.
  The Company believes Life Medical's
  claim regarding the monies received from Medpac has no merit and that, among other things, it is entitled to offset against any
  amounts that may be due Life Medical amounts that it has paid to creditors of Life Medical. Further, the Company believes that
  it and Medpac have paid the amounts necessary to maintain the rights to distribute BreastCare
  ® in Australia and that,
  among other reasons, the failure of the parties to
  due to develop a manufacturing line to produce
  the BreastCare
  ® device has extended the Company's and Medpac's obligations to expend funds in furtherance
  of the marketing of the device in Australia.
  If Life Medical pursues its claims, the Company will
  defend them vigorously and pursue any counterclaims it may have against Life Medical for actions which it believes were intentionally
  intended to interfere with the Company's attempts to raise the financing necessary to advance its products.
  Julie Singleton
  The Company had previously announced that Julie Singleton, an investor
  in MedPac, had agreed to serve as the CEO of its BreatCare Division and as a member of its Board of Directors. In light of the
  current dispute between the Company and Medpac, Ms. Singleton will not be serving in either of such positions.
  SIGNATURES
  Pursuant
  to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunto duly authorized.
  Dated: December 4, 2015
  EVENT CARDIO GROUP INC.
  By:
  /s/ John Bentivoglio
  John Bentivoglio
  Chief Executive Officer